Medicare for All without tackling the extreme consolidation in health care would just funnel money to corporate behemoths, a new report states.
Private Equity
Top Pentagon Official Contracted Personal Lawyer to Handle Pentagon Minerals Deal
Alan Waldenberg manages Stephen Feinberg’s personal trust and is lead outside counsel to his former private equity firm. He has also represented the agency where Feinberg is the number two civilian official.
Congress Face-Plants on Surprise Health Care Bills
Lawmakers wanted to reform surprise billing so patients weren’t hit with unexpected charges. But they also created a parallel system with new middlemen that is increasing health care costs.
The AI Bailout Could Be Baked Into the AI Bubble
Private credit companies are key owners of AI-related assets. Many of their parent private equity firms own life insurers that are dumping grounds for bad loans—and subject to state bailouts.
Top Defense Official Could Reap Windfall From DOD Settlement
Stephen Feinberg founded private equity giant Cerberus. A Cerberus-owned firm is poised to settle one of the largest government lawsuits ever—against the very agency Feinberg now helps lead.
Trump Funding Cuts Endangering City and Rural Hospitals Alike
A year after Trump ripped $1 trillion out of the American health care system, hundreds of hospitals have closed and millions of people are without health insurance. The majority are in urban areas.
An Unlikely Bipartisan Housing Win
The new housing law is a victory for Democratic agenda-setting, but real impact on housing costs remains elusive.
Blackstone’s Utility Gambit in New Mexico Could Slip Away
Both the firm and the utility company it’s trying to take private face potential maximum fines and a hard reset of the acquisition process for flouting New Mexico state law.
Nothing Is Safe From Private Equity Rollups
Is antitrust enforcement equal to the challenge of defeating the most prevalent abuses?
Indiana’s Private Equity Power Play
The mother lode of utility buyouts just landed on Hoosiers’ doorstep. Regulators have no say over whether the deal goes through.
